The Management of Schizophrenia in Clinical Practice (MOSAIC) Registry: A focus on patients, caregivers, illness severity, functional status, disease burden and healthcare utilization

Alphs, 2010, Validation of a 4-item Negative Symptom Assessment (NSA-4): a short, practical clinical tool for the assessment of negative symptoms in schizophrenia, Psychiatry (Edgmont), 7, 26 Ascher-Svanum, 2006, Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care, J. Clin. Psychiatry, 67, 453, 10.4088/JCP.v67n0317 Ascher-Svanum, 2010, The cost of relapse and the predictors of relapse in the treatment of schizophrenia, BMC Psychiatry, 10, 2, 10.1186/1471-244X-10-2 Birchwood, 1994, A self-report insight scale for psychosis: reliability, validity and sensitivity to change, Acta Psychiatr. Scand., 89, 62, 10.1111/j.1600-0447.1994.tb01487.x Casalino, 2003, External incentives, information technology, and organized processes to improve health care quality for patients with chronic diseases, JAMA, 289, 434, 10.1001/jama.289.4.434 Cuyún Carter, 2011, Sustained favourable long-term outcome in the treatment of schizophrenia: A 3-year prospective observational study, BMC Psychiatry, 11, 143, 10.1186/1471-244X-11-143 Haro, 2003, The European Schizophrenia outpatient health outcomes (SOHO) study: rationale, methods and recruitment, Acta. Psychiatr. Scand., 107, 222, 10.1034/j.1600-0447.2003.00064.x Haro, 2006, SOHO Study Group. 2006. Remission and relapse in the outpatient care of schizophrenia: three-year results from the schizophrenia outpatient health outcomes study, J. Clin. Psychopharmacol., 26, 571, 10.1097/01.jcp.0000246215.49271.b8 Haro, 2011, Cross-national clinical and functional remission rates: Worldwide Schizophrenia Outpatient Health Outcomes (W-SOHO) study, Br. J. Psychiatry, 199, 194, 10.1192/bjp.bp.110.082065 Haro, 2014, Understanding the impact of persistent symptoms in schizophrenia: cross-sectional findings from the Pattern study Harvey, 2011, Validating the measurement of real-world functional outcomes: phase I results of the VALERO study, Am. J. Psychiatry, 168, 1195, 10.1176/appi.ajp.2011.10121723 Harvey, 2012, Functional milestones and clinician ratings of everyday functioning in people with schizophrenia: overlap between milestones and specificity of ratings, J. Psychiatr. Res., 46, 1546, 10.1016/j.jpsychires.2012.08.018 Karagianis, 2009, Worldwide schizophrenia outpatient health outcomes (W-SOHO): baseline characteristics of pan-regional observational data from more than 17,000 patients, Int. J. Clin. Pract., 63, 1578, 10.1111/j.1742-1241.2009.02191.x Knapp, 2004, The global costs of schizophrenia, Schizophr. Bull., 30, 279, 10.1093/oxfordjournals.schbul.a007078 Kring, 2013, The clinical assessment interview for negative symptoms (CAINS): final development and validation, Am. J. Psychiatry, 170, 165, 10.1176/appi.ajp.2012.12010109 Lieberman, 2005, Effectiveness of antipsychotic drugs in patients with chronic schizophrenia, N. Engl. J. Med., 353, 1209, 10.1056/NEJMoa051688 Mansbach, 2012, The Brief Cognitive Assessment Tool (BCAT): a new test emphasizing contextual memory, executive functions, attentional capacity, and the prediction of instrumental activities of daily living, J. Clin. Exp. Neuropsychol., 34, 183, 10.1080/13803395.2011.630649 Martens, 2001, The psychological well being of family members of individuals with schizophrenia, Soc. Psychiatry Psychiatr. Epidemiol., 36, 128, 10.1007/s001270050301 Metzger, 2004 Morosini, 2000, Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning, Acta. Psychiatr. Scand., 101, 323, 10.1111/j.1600-0447.2000.tb10933.x Olivares, 2009, Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR), Eur. Psychiatry, 24, 287, 10.1016/j.eurpsy.2008.12.002 Perälä, 2007, Lifetime prevalence of psychotic and bipolar I disorders in a general population, Arch. Gen. Psychiatry, 64, 19, 10.1001/archpsyc.64.1.19 Peuskens, 2010, Treatment retention with risperidone long-acting injection: 24month results from the electronic schizophrenia adherence registry (E-STAR) in six countries, Curr. Med. Res. Opin., 26, 501, 10.1185/03007990903488670 Rocca, 2014, Negative symptoms and everyday functioning in schizophrenia: a cross-sectional study in a real world-setting, Psychiatry Res., 218, 284, 10.1016/j.psychres.2014.04.018 Saunders, 2003, Families living with severe mental illness: a literature review, Issues Ment. Health Nurs., 24, 175, 10.1080/01612840305301 Schmittdiel, 2005, Brief report: the prevalence and use of chronic disease registries in physician organizations, J. Gen. Intern. Med., 20, 855, 10.1111/j.1525-1497.2005.0171.x Tandon, 2009, Schizophrenia, “just the facts” 4. Clinical features and conceptualization, Schizophr. Res., 110, 1, 10.1016/j.schres.2009.03.005 Uggerby, 2011, Characteristics and predictors of long-term institutionalization in patients with schizophrenia, Schizophr. Res., 131, 120, 10.1016/j.schres.2011.03.001 Wilkinson, 2000, Self-report quality of life measure for people with schizophrenia: the SQLS, Br. J. Psychiatry, 177, 42, 10.1192/bjp.177.1.42 Wu, 2005, The economic burden of schizophrenia in the United States in 2002, J. Clin. Psychiatry, 66, 1122, 10.4088/JCP.v66n0906